Premium
Identification of a serum biomarker signature associated with metastatic prostate cancer
Author(s) -
Kuci Emruli Venera,
Liljedahl Leena,
Axelsson Ulrika,
Richter Corinna,
Theorin Lisa,
Bjartell Anders,
Lilja Hans,
Donovan Jenny,
Neal David,
Hamdy Freddie C.,
Borrebaeck Carl A. K.
Publication year - 2021
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.202000025
Subject(s) - prostate cancer , biomarker , medicine , oncology , cancer , prostate specific antigen , prostate , pathology , biology , biochemistry
Purpose Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.